Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in InventoryChange in ReceivablesChange in Working CapitalDeferred TaxesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet Equity Issued and RepurchasedNet Income
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNYNF) Capital Expenditures (2019 - 2025)

Historic Capital Expenditures for Sanofi (SNYNF) over the last 7 years, with Q4 2025 value amounting to -$4.1 billion.

  • Sanofi's Capital Expenditures fell 2063.75% to -$4.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$10.8 billion, marking a year-over-year decrease of 5947.84%. This contributed to the annual value of $4.0 billion for FY2025, which is 1562.23% up from last year.
  • According to the latest figures from Q4 2025, Sanofi's Capital Expenditures is -$4.1 billion, which was down 2063.75% from -$3.4 billion recorded in Q4 2024.
  • Sanofi's Capital Expenditures' 5-year high stood at -$101.4 million during Q4 2021, with a 5-year trough of -$4.1 billion in Q4 2025.
  • In the last 4 years, Sanofi's Capital Expenditures had a median value of -$3.3 billion in 2023 and averaged -$2.7 billion.
  • In the last 5 years, Sanofi's Capital Expenditures soared by 383.55% in 2021 and then plummeted by 2063.75% in 2025.
  • Over the past 4 years, Sanofi's Capital Expenditures (Quarter) stood at -$101.4 million in 2021, then crashed by 2984.86% to -$3.1 billion in 2023, then fell by 9.19% to -$3.4 billion in 2024, then dropped by 20.64% to -$4.1 billion in 2025.
  • Its Capital Expenditures stands at -$4.1 billion for Q4 2025, versus -$3.4 billion for Q4 2024 and -$3.1 billion for Q4 2023.